Nymox Pharmaceutical Corporation (NYMX) |
|
0.4027 0.005 (1.21%)
|
06-06 15:48 |
|
Open: |
0.395 |
Pre. Close: |
0.3979 |
|
High:
|
0.4084 |
Low:
|
0.395 |
|
Volume:
|
16,280 |
Market Cap:
|
37(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 4:29:35 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 0.5 One year: 0.58 |
| Support: |
Support1: 0.33 Support2: 0.27 |
| Resistance: |
Resistance1: 0.43 Resistance2: 0.5 |
| Pivot: |
0.41  |
| Moving Average: |
MA(5): 0.41 MA(20): 0.42
MA(100): 0.4 MA(250): 0.39 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 55 %D(3): 58.9 |
| RSI: |
RSI(14): 47.1 |
| 52-week: |
High: 0.74 Low: 0.18 |
| Average Vol(K): |
3-Month: 49 (K) 10-Days: 20 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NYMX ] has closed above bottom band by 26.7%. Bollinger Bands are 40.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.41 - 0.41 |
0.41 - 0.41 |
|
Low:
|
0.39 - 0.39 |
0.39 - 0.39 |
|
Close:
|
0.4 - 0.4 |
0.4 - 0.41 |
|
Company Description |
|
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas. |
Headline News |
Wed, 10 May 2023
Nymox Provides Current Update - May 10, 2023 - BioSpace
Mon, 03 Apr 2023
Nymox Provides Corporate Update - GlobeNewswire
Wed, 22 Mar 2023
How Adobe’s CFO is avoiding mass layoffs: ‘We don’t want our employees worried about when the next shoe is going to drop’ - Fortune
Tue, 21 Mar 2023
Nymox Announces Appointment of Christopher R. Riley as Chief ... - GlobeNewswire
Wed, 15 Mar 2023
Nymox Officially Granted Extension to Regain Listing Requirements - Financial Post
Mon, 05 Dec 2022
Best Penny Stocks To Buy? 4 Under $1 To Watch Now - Penny Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
91 (M) |
| Shares Float |
50 (M) |
|
% Held by Insiders
|
45 (%) |
|
% Held by Institutions
|
1.1 (%) |
|
Shares Short
|
2,080 (K) |
|
Shares Short P.Month
|
2,190 (K) |
Stock Financials |
|
EPS
|
-0.03 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.02 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-204.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.04 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-2 (M) |
|
Levered Free Cash Flow
|
-1 (M) |
Stock Valuations |
|
PE Ratio
|
-13.43 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-20.14 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-18.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
